Carregando empresa
Keep exploring
The themes Nexalin Technology is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Medical Devices
Graded A or B and worth $2B or more: A first, then the largest.
MDTMedtronic plcUS$ 131,6BA+
SYKStryker Corp.US$ 117,9BA+
EWEdwards Lifesciences CorporationUS$ 61,6BA+
GEHCGE Healthcare Technologies Inc.US$ 37,5BA
GKOSGlaukos CorpUS$ 14,5BA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 de out. de 2026CBGraded C, now B
MCKMckesson Corporation4 de nov. de 2026BAGraded B, now A
CVSCVS Health Corp4 de nov. de 2026BAGraded B, now A- EWEdwards Lifesciences Corporation4 de nov. de 2026BAGraded B, now A
- GEHCGE Healthcare Technologies Inc.28 de out. de 2026CAGraded C, now A
Como ganha dinheiro
- Device sales45%
- Equipment and replacement parts30%
- Licensing fees16%
As participações na receita são estimativas para year ended 2025-12-31, não números de um relatório oficial.
Concorre com
- Fisher Wallace Laboratories
- Flow Neuroscience
- STIMNeuroneticsC
- Tamanho
- US$ 108,8M
- Margem
- -14,4%
- BWAYBrainsWayA
- Tamanho
- US$ 394,6M
- Margem
- 15,5%
O que vende5
Gen-1
An earlier cranial electrotherapy stimulation device used by medical professionals. Nexalin continues to service previously sold or leased devices but has paused new United States sales and marketing.
Gen-2 SYNC
A clinical-use device that delivers Nexalin’s newer 15-milliamp electrical waveform. It is under United States regulatory review and clinical development.
Gen-3 HALO
A headset being studied for physician-supervised treatment at home. A United States clinical trial for insomnia is underway.
Mostrar mais 2
Nexalin NeuroCare
Software for remote patient monitoring, doctors’ clinical workflows, collection of clinical data and virtual care.
Electrodes and patient cables
Replacement treatment components sold to medical providers using Nexalin devices.
Quem compra2
- Medical professionals and clinics that use Nexalin devices with patients; licensing arrangements generally involve monthly fees, and some charge by the number of treatments.
- International distributors and customers that buy devices and related supplies; Nexalin recorded no international revenue in the six months ended 2026-06-30.
Em que se apoia e o que pode quebrá-lo
Do que o negócio depende
- 1United States sales of new devices depend on Food and Drug Administration (FDA) clearance or approval; Nexalin’s HALO insomnia study and other clinical and regulatory work are part of that process.
- 2Device assembly, testing and quality checks rely mainly on third-party manufacturers.
- 3Clinical studies rely on outside research organizations and study sites to carry out trials and recruit participants.
- 4China distribution and future device registrations depend in part on Wider, which is responsible for pursuing approvals there.
O que pode dar errado
- 1If clinical studies fail, take longer than planned or do not support regulatory applications, Nexalin may not obtain authorization to sell newer devices for the intended uses.
- 2Nexalin has limited revenue, recurring operating losses and negative operating cash flow; it says available funds are insufficient for at least twelve months from the financial statements’ issuance. Its ability to raise funds through its share-sale program is tied to continued Nasdaq listing, which was under review after a delisting determination.
- 3Nexalin depends on outside manufacturers and clinical research organizations. Delays, quality problems or failures to meet regulatory requirements could disrupt device production or clinical studies.
Demonstrações financeiras completas →
Sobre a Nexalin Technology, Inc.
Nexalin develops devices that use electrical signals delivered through electrodes on the head to stimulate the brain. Its SYNC device is intended for clinical use, while its HALO headset is being studied for physician-supervised home use; a clinical trial for insomnia is underway. Nexalin also develops software for doctors to oversee patients remotely, manage care and collect clinical information.
- Sede
- Houston, Texas
- Fundada em
- 2010
- Listada em
- Nasdaq Capital Market
- Fim do exercício
- December 31
Construído a partir dos próprios documentos de Nexalin Technology, Inc. entregues à Comissão de Valores Mobiliários dos EUA (SEC). Os números são os divulgados, com o histórico por ação recalculado para a base de ações de hoje. Isto descreve um negócio — não é recomendação de investimento nem sugestão de compra ou venda.
